分子瘤板对耐火固体瘤患者临床结果的影响:现实世界的研究
Yan Ling1, Xiao-Dong Jiao1, Bao-Dong Qin1
1Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, 200072, China.
The oncologist
|July 1, 2025
概括
分子瘤委员会 (MTB) 推的治疗方法显著改善了耐药固体瘤患者的整体存活率 (OS) 和无进展存活率 (PFS). 匹配MTB推疗法是改善瘤结果的独立因素.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 耐火固体瘤是一个重大的临床挑战,治疗选择有限.
- 分子瘤板 (MTBs) 旨在根据遗传改变个性化癌症治疗.
研究的目的:
- 评估MTB推的治疗方法是否能改善耐火实体瘤患者的临床结果.
- 评估MTB推治疗对整体生存 (OS) 和无进展生存 (PFS) 的影响.
主要方法:
- 从2017-2022年对338名耐火实体瘤患者的回顾性分析.
- 下一代测序 (NGS) 在129名接受MTB的患者中发现了可操作的分子变化.
- 在接受MTB推治疗的患者和没有接受治疗的患者之间,OS和PFS的比较.
主要成果:
- 分析了有生存数据的217名患者.
- 接受MTB推治疗的患者的中位寿命显著更长 (17.7 vs. 4.4个月) 和PFS (7.0 vs. 2.3个月).
- 推的MTB治疗与OS的0.31和PFS的0.32的危险比率有关.
结论:
- 分子瘤委员会建议改善耐火实体瘤的瘤预后.
- 基于MTB建议的匹配疗法是改善OS和PFS的独立预测因素.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K


